Samuel N. Hazen - Oct 29, 2021 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role
CEO, Director
Signature
/s/ Natalie Harrison Cline, Attorney-in-Fact
Stock symbol
HCA
Transactions as of
Oct 29, 2021
Transactions value $
-$24,748,086
Form type
4
Date filed
11/2/2021, 07:34 PM
Next filing
Feb 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Options Exercise $7.32M +153K +51.07% $47.97* 451K Oct 29, 2021 Direct
transaction HCA Common Stock Tax liability -$19.5M -77.8K -17.23% $250.46 374K Oct 29, 2021 Direct
transaction HCA Common Stock Sale -$2.15M -8.58K -2.3% $250.96 365K Nov 2, 2021 Direct F1
transaction HCA Common Stock Sale -$9.64M -38.3K -10.48% $251.84 327K Nov 2, 2021 Direct F2
transaction HCA Common Stock Sale -$797K -3.16K -0.97% $252.44 324K Nov 2, 2021 Direct F3
holding HCA Common Stock 813K Oct 29, 2021 By LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Stock Appreciation Right Options Exercise $0 -82.5K -100% $0.00* 0 Oct 29, 2021 Common Stock 82.5K $47.97 Direct F4
transaction HCA Stock Appreciation Right Options Exercise $0 -70.1K -100% $0.00* 0 Oct 29, 2021 Common Stock 70.1K $47.97 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.24 to $251.23, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.24 to $252.23, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.24 to $252.76, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015.
F5 The stock appreciation rights vested at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the achievement of certain annual EBITDA performance targets.